Recombinant Fv-Hsp70 protein mediates neuroprotection after focal cerebral ischemia in rats.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 20075343.
- Also identified by DOI 10.1161/STROKEAHA.109.572537 and PMC identifier 2957177.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study investigated the effects of intravenous recombinant Fv-Hsp70 protein on infarction volume and behavior after experimental ischemic stroke. Focal cerebral ischemia was produced by occluding the middle cerebral artery using the intraluminal suture technique. Rats subjected to 2 hours of focal ischemia were allowed to survive 24 hours. At 2(1/4) hours and 3 hours after onset of ischemia, Fv-Hsp70 recombinant protein (0.5 mg/kg) or saline was injected through the tail vein. Sensorimotor function and infarction volume were assessed at 24 hours after ischemia. Administration of Fv-Hsp70 after focal cerebral ischemia significantly decreased infarct volume by 68% and significantly improved sensorimotor function compared with the saline-treated control group. Western blots showed Fv-Hsp70 in ischemic but not in control brain; and Fv-Hsp70 suppressed endogenous Hsp70. Fv-Hsp70 protected the ischemic brain in this experimental stroke model.
Medical subject headings
- Brain Ischemia
- HSP70 Heat-Shock Proteins
- Immunoglobulin Fragments
- Lymphokines
- Neuroprotective Agents
- Recombinant Proteins
- Sialoglycoproteins